INSIGHT
MEDICA 2025 and the start of CleverSkin’s public journey
MEDICA 2025 mattered because it moved CleverSkin from internal development into external challenge. That is a different test. A team can become comfortable with its own assumptions; manufacturers, distributors, clinicians and strategic partners are less forgiving.
The useful outcome was not publicity. It was a better list of questions. Which product boundary is easiest to explain? What evidence would a serious partner need? Where does the manufacturing route create friction? Which conversations are commercial, and which are simply interest?
That is how we use events now. Not as proof that the market has accepted the product, but as a way to expose the programme to people who can find the weak points early.
INSIGHT
Early route-building in Turkey, Saudi Arabia and Brazil
A country on a pipeline is not a market-entry strategy. The route becomes real only when we understand who carries regulatory responsibility, who can manufacture or distribute, what evidence is expected and who ultimately pays.
Our work in Turkey, Saudi Arabia and Brazil has been useful because the questions are different in each market. That forces us to separate what is genuinely portable in the CleverSkin programme from what needs local adaptation.
The practical objective is simple: do the route work early enough that commercial interest does not create avoidable regulatory or operational debt later.
INSIGHT
International interest and government dialogue
We have had interest and discussions involving stakeholders in Indonesia, Vietnam, the Philippines, Canada, India, Kuwait and Germany, including government-linked and institution-linked conversations.
I do not treat a conversation as a market. What matters is what the conversation teaches us about procurement, local regulation, evidence expectations, manufacturing, public-sector adoption and the partner structure required to make a route workable.
That is the value of early international dialogue: it helps us decide where to invest attention before we invest capital.
INSIGHT
Why securing the Class I position for the first product matters
The most important regulatory decision is not always how broad a product can become. Sometimes it is how narrow the first product should be.
For CleverSkin24, securing the Class I position for the current first-aid configuration gives the programme a clearer starting point. It aligns intended use, claims discipline, evidence planning and the first commercial route.
Classification does not remove the remaining work. It does something more useful: it makes the next work easier to sequence.
INSIGHT
Why we launched an IMS early
Early-stage companies often postpone systems until they are larger. I think that is the wrong sequence for a regulated product. Complexity appears before scale.
We launched the CleverSkin IMS so that claims, evidence, decisions, suppliers, responsibilities and change control have one management structure while the programme is still changing quickly.
The objective is not paperwork. It is to reduce the chance that commercial speed, technical work and regulatory decisions drift into different versions of the same company.
INSIGHT
Why we built a 72-point scorecard
A development-stage MedTech company can look busy while still avoiding its hardest questions. That is why we built a 72-point scorecard.
The scorecard is intended to force a structured view across product, evidence, regulation, manufacturing, commercial readiness and governance. It is not a substitute for specialist judgement, and it is not a badge.
Its value is that weak points become visible. Once they are visible, management can decide whether to close them, accept them, or change the route.
INSIGHT
Why we built an Advisory Board
Founders need conviction. They also need people who are prepared to challenge it.
The CleverSkin Advisory Board was built to bring structured external challenge into the programme across clinical, regulatory, manufacturing, capital, market-access and international questions. The role is not ceremonial. A useful adviser should be able to change a decision, expose a missing assumption or shorten the route to an answer.
Management remains accountable. Advice is valuable when it improves that accountability, not when it replaces it.
INSIGHT
Starting OEM, regulatory and manufacturing-equipment conversations
Manufacturing is not something we can design on a spreadsheet and validate later. The equipment, package, process, supplier grades and host-manufacturer capabilities all shape what the product can become.
That is why we started OEM, regulatory and equipment-supplier conversations before committing to a large manufacturing build. The earlier we understand practical constraints, the less likely we are to spend capital solving the wrong problem.
The next step is representative manufacture under controlled conditions, not scale for its own sake.
INSIGHT
Advanced wound-care costs in the UK: why the burden matters
Wound care is often discussed as a product category. For the health system, it is also a repeated workload: assessment, dressing changes, staff time, consumables, complications and follow-up.
Our research into UK wound-care costs is useful because it changes the product question. A new dressing should not be judged only by whether the material is technically interesting. It has to make sense inside a real care pathway.
That means looking at total burden, not only unit price. It also means being careful not to claim an economic benefit before the evidence can support it.
INSIGHT
Why we started with CleverSkin24
A platform becomes harder to believe when the first commercial plan tries to prove everything at once.
CleverSkin24 gives us a narrower route: a defined first-aid use, controlled claims, a limited contact duration and a clearer evidence and manufacturing programme. That makes the first commercial test more useful.
The wider platform still matters. Starting narrow is how we intend to make the wider opportunity credible.
